A Professional Service Provider for the Pharma Industry
Much has already been written in recent months about avacopan / TAVNEOS, the oral complement C5a receptor antagonist. It is in the news because of the way the parent company, Chemocentryx, its Adjudication Board and the CRO handled the unblinded data and ‘re-adjudicated’ the results to achieve the desired outcome, an Continue reading Avacopan ADVOCATE Study Design
We have to thank Liu and colleagues for a thorough review of pharmaceutical development activities in China and elsewhere during the last decade.[1] The authors reviewed a total of 34,844 Phase 1-3 trials, showing a significant uptick in studies initiated by Chinese companies. Compared to 2015, trial numbers have steadily Continue reading DRUG DEVELOPMENT IN CHINA – Moving Beyond the Me-Too Path
This is a somewhat nostalgic retro blog. I was leafing through a book by Vince Andriole called ‘The Quinolones’.[1] First released in 1988, its third edition is from 2000. It provided in-depth coverage of quinolone chemistry, PK, microbiology, efficacy and safety. It was a great review of the large and Continue reading ANTIBIOTIC DEVELOPMENT IN PHARMA IS DEAD – FOR NOW